This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Menadione bisulfite
- DrugBank Accession Number
- DB15944
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Menadione bisulfite (DB15944)
- Weight
- Average: 254.26
Monoisotopic: 254.024894596 - Chemical Formula
- C11H10O5S
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAlbutrepenonacog alfa Menadione bisulfite may increase the thrombogenic activities of Albutrepenonacog alfa. Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Menadione bisulfite. Alteplase The therapeutic efficacy of Menadione bisulfite can be decreased when used in combination with Alteplase. Aminocaproic acid Aminocaproic acid may increase the thrombogenic activities of Menadione bisulfite. Andexanet alfa Menadione bisulfite may increase the thrombogenic activities of Andexanet alfa. Anistreplase The therapeutic efficacy of Menadione bisulfite can be decreased when used in combination with Anistreplase. Anti-inhibitor coagulant complex Menadione bisulfite may increase the thrombogenic activities of Anti-inhibitor coagulant complex. Antihemophilic factor (recombinant), PEGylated Menadione bisulfite may increase the thrombogenic activities of Antihemophilic factor (recombinant), PEGylated. Antihemophilic factor human Menadione bisulfite may increase the thrombogenic activities of Antihemophilic factor human. Antihemophilic factor, human recombinant Menadione bisulfite may increase the thrombogenic activities of Antihemophilic factor, human recombinant. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Menadione sodium bisulfite anhydrous 97K34V88SA 130-37-0 XDPFHGWVCTXHDX-UHFFFAOYSA-M Menadione sodium bisulfite trihydrate 6XF3C2HK77 6147-37-1 Not applicable
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- I2BE1ZEN8I
- CAS number
- 130-36-9
- InChI Key
- WIXFIQKTHUVFDI-UHFFFAOYSA-N
- InChI
- InChI=1S/C11H10O5S/c1-11(17(14,15)16)6-9(12)7-4-2-3-5-8(7)10(11)13/h2-5H,6H2,1H3,(H,14,15,16)
- IUPAC Name
- 2-methyl-1,4-dioxo-1,2,3,4-tetrahydronaphthalene-2-sulfonic acid
- SMILES
- CC1(CC(=O)C2=C(C=CC=C2)C1=O)S(O)(=O)=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 8220
- ChEBI
- 63930
- ChEMBL
- CHEMBL1159684
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Parenteral Solution Oral Solution Parenteral 50.000 mg Injection - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.86 mg/mL ALOGPS logP -0.47 ALOGPS logP 0.87 Chemaxon logS -2.1 ALOGPS pKa (Strongest Acidic) -1.5 Chemaxon pKa (Strongest Basic) -7.4 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 88.51 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 59.81 m3·mol-1 Chemaxon Polarizability 23.27 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at November 25, 2020 21:38 / Updated at September 28, 2023 00:45